Journal of Internal Medicine Concepts & Practice >
Research progress of drug-resistant gram-negative bacteria bloodstream infection in diabetic population
GAO Yulian, FENG Yun, NI Lei . Research progress of drug-resistant gram-negative bacteria bloodstream infection in diabetic population[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(02) : 124 -127 . DOI: 10.16138/j.1673-6087.2023.02.013
| [1] | Hu FP. China Antimicrobial Surveillance Network, the results of bacterial resistance in 2021[DB/OL]. 2022. https://www.chinets.com/Document. |
| [2] | Babiker A, Clarke LG, Saul M, et al. Changing epidemiology and decreased mortality associated with carbapenem-resistant Gram-negative bacteria, 2000-2017[J]. Clin Infect Dis, 2021, 73(11): e4521-e4530. |
| [3] | Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic[J]. Diabetes Care, 2016, 39(3): 472-485. |
| [4] | 鲍强, 杨荣礼, 徐敏, 等. 糖尿病合并血流感染耐药性的相关性[J]. 临床与病理杂志, 2021, 41(5): 1064-1074. |
| [5] | Huang CH, Chiu CH, Chen IW, et al. Antimicrobial resistance and outcomes of community-onset bacterial bloodstream infections in patients with type 2 diabetes[J]. J Glob Antimicrob Resist, 2018, 15: 271-276. |
| [6] | Shaik S, Ranjan A, Tiwari SK, et al. Comparative genomic analysis of globally dominant ST131 clone with other epidemiologically successful extraintestinal pathogenic Escherichia coli (ExPEC) lineages[J]. MBio, 2017, 8(5): e01596-e01617. |
| [7] | Daga AP, Koga VL, Soncini JGM, et al. Escherichia coli bloodstream infections in patients at a university hospital[J]. Front Cell Infect Microbiol, 2019, 9: 191. |
| [8] | Isendahl J, Giske CG, Hammar U, et al. Temporal dynamics and risk factors for bloodstream infection with extended-spectrum β-lactamase-producing bacteria in previously-colonized individuals[J]. Clin Infect Dis, 2018, 68(4): 641-649. |
| [9] | Tchesnokova V, Riddell K, Scholes D, et al. The uropathogenic Escherichia coli subclone sequence type 131-H30 is responsible for most antibiotic prescription errors at an urgent care clinic[J]. Clin Infect Dis, 2019, 68(5): 781-787. |
| [10] | Harada S, Aoki K, Yamamoto S, et al. Clinical and molecular characteristics of Klebsiella pneumoniae isolates causing bloodstream infections in Japan[J]. J Clin Microbiol, 2019, 57(11): e01206-e01219. |
| [11] | Liao WC, Chung WS, Lo YC, et al. Changing epidemiology and prognosis of nosocomial bloodstream infection: a single-center retrospective study in Taiwan[J]. J Microbiol Immunol Infect, 2022, 55(6 Pt 2):1293-1300. |
| [12] | Cheng CY, Kung CT, Chen FC, et al. Impact of prior statin use on mortality in patients with type 2 diabetes mellitus and bloodstream infection[J]. J Int Med Res, 2019, 47(8): 3636-3647. |
| [13] | Leung CH, Liu CP. Diabetic status and the relationship of blood glucose to mortality in adults with carbapenem-resistant Acinetobacter baumannii complex bacteremia[J]. J Microbiol Immunol Infect, 2019, 52(4): 654-662. |
| [14] | Jung JS, Hamacher C, Gross B, et al. Evaluation of a semiquantitative matrix-assisted laser desorption ionization-time of flight mass spectrometry method for rapid antimicrobial susceptibility testing of positive blood cultures[J]. J Clin Microbiol, 2016, 54(11): 2820-2824. |
| [15] | Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications[J]. Clin Microbiol Infect, 2020, 26(6): 713-722. |
| [16] | Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia[J]. J Infect, 2014, 69(3): 216-225. |
| [17] | 马丽平, 崔北辰, 关岚, 等. 2型糖尿病患者发生急性血流感染的预测指标分析[J]. 中国医刊, 2021, 56(9): 972-975. |
| [18] | Gao Q, Li Z, Mo X, et al. Combined procalcitonin and hemogram parameters contribute to early differential diagnosis of Gram-negative/Gram-positive bloodstream infections[J]. J Clin Lab Anal, 2021, 35(9):e23927. |
| [19] | 耿男, 庞燕, 张静雯, 等. 血清降钙素原诊断成人革兰阴性菌血流感染价值的Meta分析[J]. 国际检验医学杂志, 2021, 42(23): 2822-2829. |
| [20] | 侯钧, 张栋珉, 马瑜珊, 等. 糖尿病合并血流感染的病原学特征及预后危险因素分析[J]. 重庆医学, 2022, 51(15): 2622-2627. |
| [21] | Yo CH, Lee MT, Gi WT, et al. Prognostic determinants of community-acquired bloodstream infection in type 2 diabetic patients in ED[J]. Am J Emerg Med, 2014, 32(12):1450-1454. |
| [22] | Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae[J]. Crit Care, 2020, 24(1): 29. |
| [23] | Hauck C, Cober E, Richter SS, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections[J]. Clin Microbiol Infect, 2016, 22(6): 513-519. |
| [24] | Zhang Y, Chen XL, Huang AW, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies[J]. Emerg Microbes Infect, 2016, 5(3): e27. |
| [25] | Sabino S, Soares S, Ramos F, et al. A cohort study of the impact of carbapenem-resistant enterobacteriaceae infections on mortality of patients presenting with sepsis[J]. MSphere, 2019, 4(2): e00052-e00119. |
| [26] | Hu F, Guo Y, Yang Y, et al. Resistance reported from China Antimicrobial Surveillance Network(CHINET) in 2018[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(12):2275-2281. |
| [27] | 甄思思, 冯四洲. 头孢他啶-阿维巴坦在耐药菌感染中的临床应用研究进展[J]. 中国感染与化疗杂志, 2021, 21(6): 752-758. |
| [28] | Giannella M, Bartoletti M, Gatti M, et al. Advances in the therapy of bacterial bloodstream infections[J]. Clin Microbiol Infect, 2020, 26(2): 158-167. |
| [29] | 翟群超, 叶山东. 2型糖尿病合并血流感染研究进展[J]. 安徽医学, 2016, 37(9): 1176-1178. |
| [30] | Trevelin SC, Carlos D, Beretta M, et al. Diabetes mellitus and sepsis[J]. Shock, 2017, 47(3): 276-287. |
| [31] | Pearson-Stuttard J, Blundell S, Harris T, et al. Diabetes and infection: assessing the association with glycaemic control in population-based studies[J]. Lancet Diabetes Endocrinol, 2016, 4(2):148-158. |
| [32] | Critchley JA, Carey IM, Harris T, et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study[J]. Diabetes Care, 2018, 41(10): 2127-2135. |
| [33] | Sato J, Kanazawa A, Watada H. Type 2 diabetes and bacteremia[J]. Ann Nutr Metab, 2017, 71 Suppl 1: 17-22. |
| [34] | Stoudt K, Chawla S. Don’t sugar coat it[J]. J Intensive Care Med, 2019, 34(11-12):889-896. |
| [35] | Abdelmalak BB, Lansang MC. Revisiting tight glycemic control in perioperative and critically ill patients: when one size may not fit all[J]. J Clin Anesth, 2013, 25(6):499-507. |
| [36] | Yamada T, Shojima N, Noma H, et al. Glycemic control, mortality, and hypoglycemia in critically ill patients[J]. Intensive Care Med, 2017, 43(1):1-15. |
| [37] | American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43 Suppl 1:S14-S31. |
| [38] | Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377. |
/
| 〈 |
|
〉 |
